Immunoprophylaxis to Prevent Mother-to-Child Transmission of HIV-1

Journal of Acquired Immune Deficiency Syndromes

Volumn 35, Issue 2, 2004, Pages 169-177

  Safrit, Jeffrey T ^a   Ruprecht, Ruth ^b   Ferrantelli, Flavia ^b   Xu, Weidong ^b   Kitabwalla, Moiz ^b   Van Rompay, Koen ^c   Marthas, Marta ^c   Haigwood, Nancy ^d   Mascola, John R ^e   Luzuriaga, Katherine ^f   Jones, Samuel Adeniyi ^e   Mathieson, Bonnie J ^g   Newell, Marie Louise ^h  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d SEATTLE BIOMEDICAL RESEARCH INSTITUTE   (United States)

^e NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^f UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^g NATIONAL INSTITUTES OF HEALTH   (United States)

^h UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Immunoprophylaxis; Neonates; Prevention mother to child transmission; Vaccines

Indexed keywords

CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; MATERNAL ANTIBODY; MONOCLONAL ANTIBODY; POLYCLONAL ANTIBODY; SIMIAN IMMUNODEFICIENCY VIRUS VACCINE;

ACTIVE IMMUNIZATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; BREAST FEEDING; CLADISTICS; CONTROLLED STUDY; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOPROPHYLAXIS; NONHUMAN; PASSIVE IMMUNIZATION; PLACENTAL TRANSFER; PRIORITY JOURNAL; REVIEW; RHESUS MONKEY; VIRUS NEUTRALIZATION; WORLD HEALTH ORGANIZATION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; AIDS VACCINES; ANIMALS; BREAST FEEDING; DISEASE TRANSMISSION, VERTICAL; FEMALE; HIV ANTIBODIES; HIV-1; HUMANS; IMMUNIZATION, PASSIVE; INFANT, NEWBORN; MILK, HUMAN; PREGNANCY;

EID: 9144262305     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200402010-00012     Document Type: Review

References (47)

1. Pickering LK, Orenstein WA. Development of pediatric vaccine recommendations and policies. Semin Pediatr Infect Dis. 2002;3:148-154.
2. Wei X, Decker JM, Wang S, et al. Antibody neutralization and escape by HIV-1. Nature. 2003;422:307-312.
3. Richman DD, Wrin T, Little SJ, et al. Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc Natl Acad Sci U S A. 2003;100:4144-4149.
4. Geffin R, Hutto C, Andrew C, Scott G. Evolution of neutralization escape viruses in children perinatally infected with HIV-1 with rapid and non-rapid disease progression. Reported at Keystone HIV Vaccine Symposium, March 29-April 4, 2003. Banf, Canada. Abstract 413.
5. Rossi P, Moschese V, Broliden PA, et al. Presence of maternal antibodies to human immunodeficiency virus 1 envelope glycoprotein gp120 epitopes correlates with the uninfected status of children born to seropositive mothers. Proc Natl Acad Sci U S A. 1989;86:8055-8058.
6. Scarlatti G, Leitner T, Hodara V, et al. Neutralizing antibodies and viral characteristics in mother-to-child transmission of HIV-1. AIDS. 1993;7(suppl 2):S45-S48.
7. Scarlatti G, Albert J, Rossi P, et al. Mother-to-child transmission of human immunodeficiency virus type 1: correlation with neutralizing antibodies against primary isolates. J Infect Dis. 1993;168:207-210.
8. Guevera H, Casseb J, Zijehnah LS, et al. Maternal HIV-1 antibody and vertical transmission in subtype C virus infection. J Acquir Immune Defic Syndr. 2002;29:435-440.
9. Ugen KE, Srikantan V, Goedert JJ, et al. Vertical transmission of human immunodeficiency virus type 1: seroreactivity by maternal antibodies to the carboxy region of the gp41 envelope glycoprotein. J Infect Dis. 1997;175:63-69.
10. Ugen KE, Goedert JJ, Boyer J, et al. Vertical transmission of human immunodeficiency virus (HIV) infection: reactivity of maternal sera with glycoprotein 120 and 41 peptides from HIV type 1. J Clin Invest. 1992;89:1923-1930.
11. Broliden K, Sievers E, Tovo PA, et al. Antibody-dependent cellular cytotoxicity and neutralizing activity in sera of HIV-1-infected mothers and their children. Clin Exp Immunol. 1993;93:56-64.
12. Kovarik J, Siegrist CA. Optimization of vaccine responses in early life: the role of delivery systems and immunomodulators. Immunol Cell Biol. 1998;76:222-236.
13. Van Rompay KK, Berardi CJ, Dillard-Telm S, et al. Passive immunization of newborn rhesus macaques prevents oral simian immunodeficiency virus infection. J Infect Dis. 1998;177:1247-1259.
14. Mascola J, Lewis MG, Stiegler G, et al. Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of nuetralizing antibodies. J Virol. 1999;73:4009-4018.
15. Baba TW, Liska V, Hofmann-Lehmann R, et al. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection. Nat Med. 2000;2:200-206.
16. Hofmann-Lehmann R, Vlasak J, Rasmussen RA, et al. Postnatal passive immunization of neonatal macaques with a triple combination of human monoclonal antibodies against oral simian-human immunodeficiency virus challenge. J Virol. 2001;75:7470-7480.
17. Hofmann-Lehmann R, Vlasak J, Rasmussen RA, et al. Postnatal pre- and postexposure passive immunization Strategies: protection of neonatal macaques against oral simian-human immunodeficiency virus challenge. J Med Primatol. 2002;3:109-119.
18. Ferrantelli F, Hofmann-Lehmann R, Rasmussen RA, et al. Post-exposure prophylaxis with human monoclonal antibodies prevented SHIV89.6P infection or disease in neonatal macaques. AIDS. 2003;17:301-309.
19. Posner MR, Hideshima T, Cannon T, et al. An IgG human monoclonal antibody that reacts with HIV-1/GP120, inhibits virus binding to cells, and neutralizes infection. J Immunol. 1991;146:4325-4332.
20. Roben P, Moore JP, Thali M, et al. Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1. J Virol. 1994;68:4821-4828.
21. Trkola A, Purtscher M, Muster T, et al. Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J Virol. 1996;70:1100-1108.
22. Muster T, Steindl F, Purtscher M, et al. A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J Virol. 1993;67:6642-6647.
23. Zwick MB, Labrijn AF, Wang M, et al. Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41. J Virol. 2001;75:10892-10905.
24. Reimann KA, Li JT, Veazey R, et al. A chimeric simian/human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate env causes an AIDS-like disease after in vivo passage in rhesus monkeys. J Virol. 1996;70:6922-6928.
25. Feinberg MB, Moore JP. AIDS Vaccine models: challenging challenge viruses. Nat Med. 2002;8:207-210.
26. Montefiore DC, Reimann KA, Wyand MS, et al. Neutralizing antibodies in sera from macaques infected with chimeric simian-human immunodeficiency virus containing the envelope glycoproteins of either a laboratory-adapted variant or a primary isolate of human immunodeficiency virus. J Virol. 1998;72:3427-3431.
27. Harouse JM, Gettic A, Eshetu T, et al. Mucosal transmission and induction of simian AIDS by CCR5-specific simian/human immunodeficiency virus SHIV(SF162P3). J Virol. 2001;75:1990-1995.
28. McCutchan FE. Understanding the genetic diversity of HIV-1. AIDS. 2000;14(suppl 3):S31-S44.
29. Thompson MM, Perez-Alvarez L, Najera R. Molecular epidemiology of HIV-1 genetic forms and its significance for vaccine development and therapy. Lancet Infect Dis. 2002;2:461-471.
30. Xu W, Smith-Franklin BA, Li PL, et al. Potent neutralization of primary human immunodeficiency virus clade C isolates with a synergistic combination of human monoclonal antibodies raised against clade B. J Hum Virol. 2001;4:55-61.
31. Zwick MB, Wang M, Poignard P, et al. Neutralization synergy of human immunodeficiency virus type 1 primary isolates by cocktails of broadly neutralizing antibodies. J Virol. 2001;75:12198-12208.
32. Kitabwalla M, Ferrantelli F, Wang T, et al. Primary African HIV clade A and D isolates: effective cross-clade neutralization with a quadruple combination of human monoclonal antibodies raised against clade B. AIDS Res Hum Retroviruses. 2003;19:125-131.
33. Cavacini LA, Samore MH, Gambertoglio J, et al. Phase 1 study of human monoclonal antibody directed against the CD4-binding site of HIV type 1 glycoprotein 120. AIDS Res Hum Retroviruses. 1998;14:545-550.
34. Armbruster C, Stiegler GM, Vcelar BA, et al. A phase I trial with two human monoclonal antibodies (hMAb 2F5, 2G12) against HIV-1. AIDS. 2002;16:227-233.
35. Stiegler G, Armbruster C, Vcelar B, et al. Antiviral activity of the neutralizing antibodies 2F5 and 2G12 in asymptomatic HIV-1-infected humans: a phase I evaluation. AIDS. 2002;16:2019-2025.
36. Lambert JS, Mofenson LM, Fletcher CV, et al. Safety and pharmacokinetics of hyperimmune anti-human immunodeficiency virus (HIV) immunoglobulin administered to HIV-infected pregnant women and their newborns. Pediatric AIDS Clinical Trials Group Protocol 185 Pharmacokinetic Study Group. J Infect Dis. 1997;175:283-291.
37. Stichm ER, Lambert JS, Mofenson LM, et al. Efficacy of zidovudine and human immunodeficiency virus (HIV) hyperimmune immunoglobulin for reducing perinatal HIV transmission from HIV-infected women with advanced disease: results of Pediatric AIDS Clinical Trials Group protocol 185. J Infect Dis. 1999;179:567-575.
38. Guay LA, Musoke P, Hom DL, et al. Phase I/II trial of HIV-1 hyperimmune globulin for the prevention of HIV-1 vertical transmission in Uganda. AIDS. 2002;16:1391-1400.
39. Van Rompay KK, Otsyula MG, Tarara RP, et al. Vaccination of pregnant macaques protects newborns against mucosal simian immunodeficiency virus infection. J Infect Dis. 1996;173:1327-1335.
40. Van Rompay KK, Greenier JL, Cole KS, et al. Immunization of newborn rhesus macaques with simian immunodeficiency virus (SIV) vaccines prolongs survival after oral challenge with virulent SIVmac251. J Virol. 2003;77:179-190.
41. Rasmussen RA, Hofmann-Lehman R, Montefiori DC, et al. DNA prime/protein boost vaccine strategy in neonatal macaques against simian human immunodeficiency virus. J Med Primatol. 2002;31:40-60.
42. Robinson HL, Montefiore DC, Johnson RP, et al. Neutralizing antibody-independent containment of immunodeficiency virus challenges by DNA priming and recombinant pox virus booster immunizations. Nat Med. 1999;5:526-534.
43. Safrit JT. HIV vaccines in infants and children: past trials, present plans and future perspectives. Curr Mol Med. 2003;3:309-318.
44. Moss B. Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety. Proc Natl Acad Sci U S A. 1996;93:11341-11348.
45. Levine AM, Groshen S, Allen J, et al. Initial studies on active immunization of HIV-infected subjects using a gp120-depleted HIV-1 immunogen: long-term follow-up. J Acquir Immune Defic Syndr Hum Retrovirol. 1996;11:351-364.
46. Sutter G, Moss B. Nonreplicating vaccinia vector efficiently expresses recombinant genes. Proc Natl Acad Sci U S A. 1992;89:10847-10851.
47. Ferrantelli F, Ruprecht RM. Neutralizing antibodies against HIV: back in the major leagues? Curr Opin Immunol. 2002;14:495-502.